Biologic predictors in follicular lymphoma: Importance of markers of immune response

References

• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Montoto S, Lopez-Guillermo A, Altes A, Perea G, Ferrer A, Camos M, et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004; 15: 1484–1489
   PubMed Web of Science ®Google Scholar
• Martin A R, Weisenburger D D, Chan W C, Ruby E I, Anderson J R, Vose J M, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85: 3671–3678
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Vose J M, Hock L M, Lynch J C, Aoun P, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363–2367
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Cabanillas F, McDonnell T I, Mclaughlin P, Smith T, Pugh W, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999; 93: 3081–3087
   PubMed Web of Science ®Google Scholar
• Weisenburger D D, Gascoyne R D, Bierman P J, Shenkier T, Horsman D E, Lynch J C, et al. Clinical significance of the t(14;18) and BCL2 overexpression in follicular large cell lymphoma. Leuk Lymphoma 2000; 36: 513–523
   PubMed Web of Science ®Google Scholar
• Viardot A, Moller P, Hogel J, Werner K, Mechtersheimer G, Ho A D, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol 2002; 20: 4523–4530
   PubMed Web of Science ®Google Scholar
• Llanos M, Alvarez-Arguelles H, Aleman R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001; 18: 15–22
   PubMed Web of Science ®Google Scholar
• Bilalovic N, Blystad A K, Golouh R, Nesland J M, Selak I, Trinh D, et al. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol 2004; 121: 34–42
   PubMed Web of Science ®Google Scholar
• Moller M B, Nielsen O, Pedersen N T. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology 2002; 41: 322–330
   PubMed Web of Science ®Google Scholar
• Besa P C, McLaughlin P W, Cox J D, Fuller L M. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 1995; 75: 2361–2367
   PubMed Web of Science ®Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider B F, Shumansky K, Spinelli J J, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169–2174
   PubMed Web of Science ®Google Scholar
• Farinha P, Campo E, Banham A, Masoudi H, Skinnider B F, Connors J M, et al. The architectural pattern of FOXP3+ T-cells is an indpendent predictor of survival in patients with follicular lymphoma. Mod Pathol 2006; 19: 1043a
   Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox B C, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor infiltrating FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957–2964
   PubMed Web of Science ®Google Scholar
• Lee A M, Clear A J, Calaminici M, Davies A J, Jordan S, Macdougall F, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 2052–2059
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado M T, Lopez C, Jaen J, Bosch R, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350–5357
   PubMed Web of Science ®Google Scholar
• Mann R B, Berard C W. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1983; 1: 187–192
   PubMedGoogle Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J. Tumours of Haematopoeitic and Lymphoid Tissues. 2001
   Google Scholar
• Sup S J, Alemany C A, Pohlman B, Elson P, Malhi S, Thakkar S, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005; 23: 3773–3779
   PubMed Web of Science ®Google Scholar
• Fisher R I, LeBlanc M, Press O W, Maloney D G, Unger J M, Miller T P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
   PubMed Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F, Hagemeister F B, Ayers G D, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582–1589
   PubMed Web of Science ®Google Scholar
• Morel P, Dupriez B, Plantier-Colcher I, Gosselin B, Declercq C, Pollet J P, et al. Long-term outcome of follicular low-grade lymphoma. A report of 91 patients. Ann Hematol 1993; 66: 303–308
   PubMed Web of Science ®Google Scholar
• Aviles A, Diaz-Maqueo J C, Sanchez E, Cortes H D, Ayala J R. Long-term results in patients with low-grade nodular non-Hodgkin's lymphoma. A randomized trial comparing chemotherapy plus radiotherapy with chemotherapy alone. Acta Oncol 1991; 30: 329–333
   PubMed Web of Science ®Google Scholar
• Dogan A, Du M Q, Aiello A, Diss T C, Ye H T, Pan L X, et al. Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood 1998; 91: 4708–4714
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Warnke R A, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686–694
   PubMed Web of Science ®Google Scholar
• Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084–2092
   PubMed Web of Science ®Google Scholar
• Gaidano G, Carbone A. MUM1: a step ahead toward the understanding of lymphoma histogenesis. Leukemia 2000; 14: 563–566
   PubMed Web of Science ®Google Scholar
• Naresh K N. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 2007; 92: 267–268
   PubMed Web of Science ®Google Scholar
• Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, et al. CD10(−)MUM1(+) follicular lymphoma lacks BCL2 translocation and shows characteristic biological and clinical features. Blood 2007; 109: 3076–3079
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Poulsen C B, Borup R, Nielsen F C, Borregaard N, Hansen M, Gronbaek K, et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol 2005; 74: 453–465
   PubMed Web of Science ®Google Scholar
• Chang C C, McClintock S, Cleveland R P, Trzpuc T, Vesole D H, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464–470
   PubMed Web of Science ®Google Scholar
• Chang C C, Lorek J, Sabath D E, Li Y, Chitambar C R, Logan B, et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 4671–4675
   PubMed Web of Science ®Google Scholar
• Uranishi M, Iida S, Sanda T, Ishida T, Tajima E, Ito M, et al. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-γ (MIG) gene expression in B-cell malignancy. Leukemia 2005; 19: 1471–1478
   PubMed Web of Science ®Google Scholar
• Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004; 6: 745–751
   PubMed Web of Science ®Google Scholar
• Yang Z Z, Novak A J, Stenson M J, Witzig T E, Ansell S M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639–3646
   PubMed Web of Science ®Google Scholar
• Ziegler S F. FOXP3: of mice and men. Annu Rev Immunol 2006; 24: 209–226
   PubMed Web of Science ®Google Scholar
• Curiel T J, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf A M, Rumpold H, Fiegl H, Zeimet A G, Muller-Holzner E, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 8326–8331
   PubMed Web of Science ®Google Scholar
• Yang Z Z, Novak A J, Ziesmer S C, Witzig T E, Ansell S M. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 10145–10152
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Camacho F I, Salvado M T, Sanchez L, Garcia J F, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006; 91: 1605–1612
   PubMed Web of Science ®Google Scholar
• Winter J N, Weller E A, Horning S J, Krajewska M, Variakojis D, Habermann T M, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207–4213
   PubMed Web of Science ®Google Scholar